Safety and Tolerability of mRNA COVID-19 Vaccines in Kidney Transplant Recipients.

ABSTRACT:

Background

COVID-19 mRNA vaccines have demonstrated excellent short-term safety in phase 3 trials. However, no kidney transplant recipients (KTR) were included. The aim of the study was to assess the safety and tolerability of COVID-19 mRNA vaccines in KTR.

Materials and methods

A longitudinal controlled study was conducted in 300 KTR and 143 control patients (CRL) without chronic kidney disease who had received 2-dose vaccinations with the mRNA vaccine. Solicited local and systemic reactogenicity and unsolicited adverse events were assessed with a standardized questionnaire. The toxicity grading scales were derived from the FDA guidelines.

Results

KTR (62.7% men) with a median (interquartile range) age of 53 (41-63) and transplant vintage of 7.25 (3-13) years did not

SUBMITTER: Slizien Z 

PROVIDER: S-EPMC8926897 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature